Clotrimazole is a broad-spectrum synthetic imidazole antifungal agent used primarily for the topical treatment of superficial fungal infections. It acts by inhibiting ergosterol synthesis, a critical component of fungal cell membranes, leading to increased membrane permeability and cell death. In the Indian context, it is a first-line, widely available, and cost-effective treatment for vulvovaginal candidiasis (VVC) and other dermatomycoses.
Adult: Vaginal: 100mg intravaginally once daily at bedtime for 6-7 days, or a single 500mg dose (different formulation). Topical: Apply a thin layer to affected area 2-3 times daily for 2-4 weeks.
Note: Vaginal Tablet: Use applicator for insertion high into the vagina at bedtime. Wash hands before and after. Topical: Clean and dry area thoroughly before application. Gently rub in a thin layer. Wash hands after application unless hands are being treated.
Clotrimazole is a fungistatic and fungicidal agent. It inhibits the fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase. This inhibition blocks the conversion of lanosterol to ergosterol, an essential sterol component of the fungal cell membrane.
Pregnancy: Pregnancy Category B (US FDA). Considered safe for use in the 2nd and 3rd trimesters. Use in the first trimester only if potential benefit justifies potential risk. Applicator insertion should be done carefully.
Driving: No effect.
| Amphotericin B | Potential antagonistic antifungal effect in vitro; clinical significance for topical use is minimal. | Moderate |
| CYP3A4 Substrates (e.g., Cyclosporine, Tacrolimus) | Theoretical interaction if significant systemic absorption occurs; unlikely with topical/vaginal use. | Minor |
| Vaginal Spermicides (e.g., Nonoxynol-9) | May inactivate clotrimazole; avoid concurrent use with vaginal formulations. | Moderate |